Incyte Genomics Inc

XNASHealth care

Last traded price · USD

$124.00

+5.45%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:27 IST · A quote does not mean the product is available to trade on your account.

Day's open: $117.52
Previous close: $117.59
Volume: 2.1M
Day's high: $123.33
Day's low: $117.52

In brief

Incyte Genomics Inc is a health care company listed on Nasdaq, valued at about $25.28B.
Its shares closed at $122.85 on 4 Nov 2026, up 19.4% over the past year.
From India you can buy INCY in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Incyte Genomics Inc (INCY) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole INCY share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade INCY options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

5.3 days to cover short interest
10.0M shares were sold short at the 15 Oct 2026 settlement, 4.9% of the 203.8M shares outstanding; covering them would take 5.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +9.0% (SPY −1.6%, XLV +13.5%). 3 months: +2.5% (SPY −0.4%, XLV +15.5%). 1 year: +19.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: INCY, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $122.85 was 2.4% above its 50-day average ($119.99) and 13.4% above its 200-day average ($108.29). It has closed above the 200-day for 108 sessions, since 3 Jun 2026. The 50-day average crossed above the 200-day on 30 Jul 2025, 319 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
78% of the way up its 52-week range
Closed at $122.85 on 4 Nov 2026: 7.4% below the 52-week high of $132.60 (28 Jul 2026) and 37.6% above the low of $89.25 (24 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+9.0%

6 months+23.0%

1 year+19.4%

5 years+82.0%

Newswire

About

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Website

Notable moves

July 28, 2026
+9.30%
July 29, 2025
+10.28%
October 29, 2024
+12.04%

Newswire

About

Website

Notable moves

July 28, 2026
+9.30%
July 29, 2025
+10.28%
October 29, 2024
+12.04%

Incyte Genomics Inc

XNASHealth care

Last traded price · USD

$124.00

+5.45%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:27 IST · A quote does not mean the product is available to trade on your account.

Day's open: $117.52
Previous close: $117.59
Volume: 2.1M
Day's high: $123.33
Day's low: $117.52

In brief

Incyte Genomics Inc is a health care company listed on Nasdaq, valued at about $25.28B.
Its shares closed at $122.85 on 4 Nov 2026, up 19.4% over the past year.
From India you can buy INCY in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Incyte Genomics Inc (INCY) shares from India?

Do I need the price of a whole INCY share to invest?

How much can I invest in US stocks in a year?

Can I trade INCY options or futures?

Insights

Quotes run fifteen minutes behind.

5.3 days to cover short interest
10.0M shares were sold short at the 15 Oct 2026 settlement, 4.9% of the 203.8M shares outstanding; covering them would take 5.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +9.0% (SPY −1.6%, XLV +13.5%). 3 months: +2.5% (SPY −0.4%, XLV +15.5%). 1 year: +19.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: INCY, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $122.85 was 2.4% above its 50-day average ($119.99) and 13.4% above its 200-day average ($108.29). It has closed above the 200-day for 108 sessions, since 3 Jun 2026. The 50-day average crossed above the 200-day on 30 Jul 2025, 319 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
78% of the way up its 52-week range
Closed at $122.85 on 4 Nov 2026: 7.4% below the 52-week high of $132.60 (28 Jul 2026) and 37.6% above the low of $89.25 (24 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+9.0%

6 months+23.0%

1 year+19.4%

5 years+82.0%

Newswire

About

Website

Notable moves

July 28, 2026
+9.30%
July 29, 2025
+10.28%
October 29, 2024
+12.04%

Newswire

About

Website

Notable moves

July 28, 2026
+9.30%
July 29, 2025
+10.28%
October 29, 2024
+12.04%

Incyte Genomics Inc

Incyte Genomics Inc in brief

5.3 days to cover short interest

Ahead of SPY, behind its sector fund XLV over 1 year

Above its 50- and 200-day averages

78% of the way up its 52-week range

Incyte Genomics Inc

Incyte Genomics Inc in brief

5.3 days to cover short interest

Ahead of SPY, behind its sector fund XLV over 1 year

Above its 50- and 200-day averages

78% of the way up its 52-week range